Global Market for Regenerative Medicine 2019
The Regenerative Medicine (RM) Industry has been rapidly expanding in recent years, making it a high-value, fast-growth market. Key drivers for the market include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
There are now accelerated pathways for advanced therapy medicinal products (ATMPs) in several countries worldwide, including the U.S., Japan, and South Korea. Legislation took effect in Japan in late 2014, in South Korea in 2016, and in the United States in 2017. Additionally, the EU has a program for product acceleration – the Adaptive Pathways. These historic events demonstrate to investors, the public, and funding providers alike that regenerative medicine is a sector that has emerged, no longer one that is evolving in the future.
“Big Pharma” is also demonstrating snowballing interest in regenerative medicine. At its core, this is a strategic way for pharmaceutical companies to diversity their product development pipeline. Much of this interest has been driven by progress with immunotherapy treatments, such as CAR-T cell therapies, most notably, Kymriah and Yescarta. After attaining FDA approvals, these two products achieved historic approvals across varied geographic markets, providing hope to millions of cancer patients worldwide.
The Regenerative Medicine (RM) Industry also saw venture capital investment expand from a mere $200 million in 2010 to a stunning $14.6 billion in 2018. This upsurge in venture capital investment represents growth of 7,300% over an eight-year period. Aggressive construction of cell and gene therapy manufacturing facilities is also being undertaken by biotech companies seeking their own production capabilities, as well as by CDMOs planning to serve third-party clients from across the RM sector. With more than 900+ brave companies composing the marketplace, regenerative medicine advances are truly disrupting healthcare.
The Regenerative Medicine (RM) Industry includes companies that are developing:
• Stem cell therapies
• Cellular therapies
• Gene therapies
• Tissue engineering
• Direct cell reprogramming
• Exosome therapies
• Cellular scaffolds and matrices
• 3D bioprinting
• Biomaterials
• Combination Products
• And More
As the first and only market research firm to specialize in the stem cell industry, BioInformant has an exceptional and unique understanding of the Regenerative Medicine (RM) Industry. Founded in 2006, BioInformant has collected over 13 years of historical data on the RM industry, providing it with a robust historical database of data on which to make future market projections. Headquartered in Washington, DC, BioInformant is strategically positioned near industry lawmakers, the National Institutes of Health (N.I.H.), the U.S. FDA, and the Maryland Biotech Corridor, among other critical resources.
In addition to leveraging an experienced team of analysts, this experience provides BioInformant with access to Key Opinion Leaders (KOLs) from across the RM sector, including dozens of executives who were interviewed for this report. To date, BioInformant has interviewed leadership from FUJIFILM, Pluristem Therapeutics, Cynata Therapeutics, RooserBio, Celularity, Hemostemix, Glycostem, Accellta, ORIG3N, Gamida Cell, Nohla Therapeutics, Fortuna Fix, Avery Therapeutics, Stem Cell Medicine Ltd., Minerva Biotechnologies, Celyad, Universal Cells, Rhemastem, and hundreds of others. With research cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine, BioInformant serves Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs.
Claim this global strategic report to learn:
• Rates of Regenerative Medicine (RM) Industry Patents, Grants, and Scientific Publications
• RM Clinical Trial Activity by Type, Stage, Sponsor, and Geography
• Market Size Determinations with 5-Year Projections
• Emerging Market Opportunities and Threats
• Approved RM Products, including Dates of Approval and Market Pricing
• Geographic Forces Impacting the RM Industry
• Regulatory Pathways and Accelerated Approval Programs
• Profiles for Leading Market Competitors
• And Much More
- REPORT OVERVIEW
- Statement of the Report
- Executive Summary
- REGENERATIVE MEDICINE (RM): AN INTRODUCTION
- A bird's Eye View of the RM Industry
- Number of RM Companies
- Table Number of RM Companies by Geography, 2018
- Major Therapeutic Platforms and Enabling Technologies in RM Industry
- Table Major Therapeutic Platforms and Enabling Technologies in RM Industry
- RM Product Approvals in 2017/2018
- Table RM Product Approvals in 2017/2018
- Total RM Clinical Trials
- Table Total RM Clinical Trials by Phase, 2017/2018
- Total RM Clinical Trials by Technology Type
- Table Total RM Clinical Trials by Technology Type
- Patient Impact of Three U.S.-Approved RM Products, 2018
- Table Patient Impact of Three RM Products, 2018
- Select Anticipated RM Industry Clinical Trial Data Readouts: 2019
- Table Select Anticipated RM Industry Clinical Trial Data Readouts: 2019
- Number of RM Companies
- RM Industry-Total Global Financings: 2018
- Table RM Industry-Total Global Financings, 2018
- Total Financings to RM Industry by Type and Year, 2016-2018
- Table Total Financings to RM Industry by Type and Year, 2016-2018
- Corporate Partnerships (Upfront Payments) in RM Industry, 2018
- Table Corporate Partnerships (Upfront Payments) in RM Industry, 2018
- Private Placements and Venture Financings in RM Industry, 2018
- Table Private Placements and Venture Financings in RM Industry, 2018
- Public Offerings (IPOs & Follo-Ons) in RM Industry, 2018
- Table Public Offerings (IPOs & Follow-Ons) in RM Industry, 2018
- Total Merger & Acquisition within RM Industry by Year, 2016-2018
- Table Total Merger & Acquisitions Within RM Industry by Year, 2015-2018
- Market Access for Regenerative Medicines as of January 2019
- Table Market Access for Regenerative Medicines as of January 2019
- Anticipated RM Product Launches
- Anticipated RM Treated Patient Numbers
- Top 20 RM Companies by Pipeline Size
- Table Top 20 RM Companies by Pipeline Size
- RM Research Institutes
- RM Research Institutes in the U.S.
- Table RM Research Institutes in North America
- RM Research Institutes in Europe
- Table RM Research Institutes in Europe
- RM Research Institutions in Australia
- Table RM Research Institutes in Australia
- University Research to Products in the Market
- Table From University Research to Products in the Market
- RM Research Institutes in the U.S.
- A bird's Eye View of the RM Industry
- CELL THERAPY (CT): AN OVERVIEW
- Cell Therapy Timeline
- Table Timeline of Notable Events in Cell Therapy Sector
- Types of Stem Cells Used in Cell Therapy
- Hematopoietic Stem Cells (HSCs)
- Table Common Indications for HSCT
- Induced Pluripotent Stem Cells (iPSCs)
- Table Leading iPS Cell Therapy Companies
- Mesenchymal Stem Cells (MSCs)
- Table MSC-Based Products with Marketing Approval (MA)
- Hematopoietic Stem Cells (HSCs)
- Neural Stem Cells (NSCs)
- Table Select List of Companies Active in Clinical Trials using Neural Stem Cells
- Indications Addressed by NSCs in Clinical Trials
- Embryonic Stem Cells (ESCs)
- Clinical Trials using Human Embryonic Stem Cells (hESCs)
- Table Select Clinical Trials that Use hESCs
- Number of Clinical Trials using hESC-Derived Cells in 2018
- Table The 29 Clinical Trials using hESCs, 2018
- Clinical Trials using Human Embryonic Stem Cells (hESCs)
- Notable Events in Cell Therapy Space in 2018
- Table Select Events in Cell Therapy Sector, 2018
- Top 15 Cell Therapy Companies
- Table Top 15 Cell and Gene Therapy Biotechs to Watch
- Cell Therapy Timeline
- GENE-MODIFIED CELL THERAPY & IMMUNOTHERAPIES
- Number of Companies Developing Gene-Modified Cell Therapy Products
- Table Number of Companies Developing Gene-Modified Cell Therapy Products
- CAR-T Cell Therapy
- Global Distribution of CAR-T Cell Therapy Companies
- Table Geographical Distribution of CAR-T Cell Therapy Companies
- Select Events in Cell-Based Immuno-Onclogy Space, 2018
- Table Select Events in Cell-Based Immuno-Onclogy Space, 2018
- Global Distribution of CAR-T Cell Therapy Companies
- T-Cell Receptor (TCR) Therapy
- Table Examples of Clinical Trials Involving T-Cell Receptors (TCRs)
- Natural Killer (NK) Cell Therapies
- Table Select NK Cell Therapies in Clinical and Preclinical Development for Cancer
- Tumor Infiltrating Lymphocytes (TILs) Therapy
- Table Examples of Clinical Trials using TILs
- Marrow-Infiltrating Lymphocytes (MILs)
- Gamma-Delta T-Cells Therapy
- Big Biopharma's Interest in Gamma-Delta T-Cells Therapy
- Table Known Gamma-Delta T-Cell Therapy Companies
- Big Biopharma's Interest in Gamma-Delta T-Cells Therapy
- Dendritic Cell (DC) Therapy
- Cancer Types Targeted by Dendritic Cell Therapy Studies
- Ongoing Clinical Trials Testing DC Vaccines
- Table Select Ongoing Clinical Trials Testing DC Vaccines
- Number of Companies Developing Gene-Modified Cell Therapy Products
- GENE THERAPY
- Gene Augmentation Therapy
- Gene Inhibition Therapy
- Suicide Gene Therapy
- The Process of DNA Transfer in Gene Therapy
- Ex vivo vs. in vivo Gene Therapies
- Table Approved Gene Therapy Products (ex vivo and in vivo)
- Ex vivo Gene Therapy
- In vivo Gene Therapy
- Autologous vs. Allogeneic Gene Therapies in Development
- Number of Gene Therapy Companies in the World
- Table Number of Gene and Gene-Based Medicine Companies by Geography
- Gene Therapy Pipeline Volumes, 1995-2018
- Big Pharma and Gene Therapy Development
- Number of Gene Therapy Products Predicted to be Approved in Next Three Years
- Gene Therapy Product Candidates Granted RMAT Designation
- Table Gene Therapy Product Candidates Granted RMAT Designation, 2018
- Gene Therapy Companies Active in Neurodegenerative Disorders (ND)
- Table Gene Therapy Companies Active in ND by Region, 2018
- Gene Therapy Developers for Neurodegenerative Diseases
- Table Gene Therapy Developers for Neurodegenerative Disorders, 2018
- Neurodegenerative Disorders Addressed by Gene Therapy Studies
- Table Neurodegenerative Disorders Addressed by Gene Therapy Studies
- Anticipated Events in Neurodegenerative Disease Space of Gene Therapy
- Table Select Anticipated Events in ND Space of Gene Therapy, 2018
- Important Events in Gene Therapy Space in 2018
- Table Select Events in Gene Therapy and Genome Editing Space, 2017/2018
- Leading Gene Therapy Startups
- Table Leading Gene Therapy Startups
- TISSUE ENGINEERING
- Smart Biomaterials in TE
- Biosynthetic Materials
- 3D Printable Inks
- Synthetic and Naturally-Derived Scaffolds
- Tissue Substitutes
- Cell-Based Tissues
- Collagen
- Table Approved TE Products
- Two Key Developments in Tissue Engineering Space in 2018
- Table Select Events in Tissue Engineering Sector, 2018
- Smart Biomaterials in TE
- GENE DELIVERY VEHICLES
- Viral Vectors
- Physical Properties of Commonly used Viral Vectors
- Table Physical Properties of Commonly used Viral Vectors
- Retrovirus Vectors
- Table Retroviruses: A Snapshot
- Adenovirus Vectors
- Table Adenoviruses: A Snapshot
- Herpes Simplex Viral Vectors
- Table Herpes Simplex Viruses (HSV): A Snapshot
- Lentivirus Vectors (LV)
- Table Lentiviruses: A Snapshot
- Adeno-Associated Virus Vectors
- Table Adeno-Associated Viruses: A Snapshot
- Table Genes Transduced by AAV for Specific Diseases
- Table Dominating Viral Vectors in Gene Therapy Drug Development
- Physical Properties of Commonly used Viral Vectors
- Non-Viral Vectors
- Microinjection
- Table Microinjection Method of Gene Delivery
- Particle Bombardment
- Table Particle Bombardment Method of Gene Delivery
- Laser Irradiation
- Table Laser Irradiation Method of Gene Delivery
- Electroporation
- Table Electroporation Method of Gene Delivery
- Magnetofection
- Table Magnetofection Method of Gene Delivery
- Sonoporation
- Table Sonoporation Method of Gene Delivery
- Microinjection
- Viral Vectors
- RM: CLINICAL TRIAL LANDSCAPE
- Table Number of Clinical Trials in RM Sector, 2017-2018
- Number of People Participating in RM Clinical Trials
- Table Number of Patient Participation in RM Clinical Trials, 2018
- Clinical Trials by Therapeutic Category in the RM Sector, 2018
- Table Clinical Trials by Therapeutic Category in the RM Sector, 2018
- Cell Therapy Clinical Trials
- Table Number of Cell Therapy Clinical Trials, 2017-2018
- Cell Therapy Clinical Trials by Indication
- Mesenchymal Stem Cells in Clinical Trials
- Table Number of Clinical Trials using MSCs
- Anticipated Clinical Events in Cell Therapy Space
- Table Select Anticipated Clinical Data and Events in Cell Therapy Space
- Clinical Trials in Gene-Modified Cell Therapies Space
- Table Number of Gene-Modified Cell Therapy Clinical Trials, 2017-2018
- Most Popular Target Antigens for CAR-T Cell Therapies
- Antigens other Than CD19 in Clinical Trials Targeted by CAR-T
- Table Antigens other Than CD19 in Clinical Trials Targeted by CAR-T
- Antigens Targeted by CAR-T in Solid Cancers in Clinical Trials
- Anticipated Developments in CAR-T Space
- Table Select Anticipated Clinical Data and Events in CAR-T Cell Therapy Sector
- Number of Gene Therapy Clinical Trials
- Table Number of Gene Therapy Clinical Trials, 2017-2018
- Therapy Clinical Trials by Geography
- Table Gene Therapy Clinical Trials by Geography
- Diseases Targeted by Gene Therapy
- Table Diseases Targeted by Gene Therapy, 2018
- Gene Types Transduced in Clinical Trials
- Table Gene Types Transduced in Clinical Trials, 2018
- Vectors used in Gene Therapy Clinical Trials
- Table Vectors used in Gene Therapy Clinical Trials, 2018
- Gene Therapy Clinical Trials for Neurodegenerative Indications by Type
- Table Gene Therapy Clinical Trials for Neurodegenerative Indications by Type, 2018
- Domination of Oncology in Gene Therapy Drug Development
- Table Domination of Oncology in Gene Therapy Drug Development
- Dominance of Viral Vectors in Gene Therapy
- Gene Therapy Alliances Volume and Value, 2012-2018
- Table Gene Therapy Alliances Volume and Value, 2012-2018
- Anticipated Clinical Events in Gene Therapy Space, 2019/2020
- Table Select Anticipated Clinical Data and Events in Gene Therapy Sector
- Number of Tissue Engineering Clinical Trials
- Table Number of Clinical Trials in TE Space, 2017-2018
- Anticipated Clinical Events in Tissue Engineering Space
- Table Select Anticipated Clinical Data and Events in Tissue Engineering Space
- APPROVED RM PRODUCTS WORLDWIDE
- Number of RM Products Approved by Geography
- Table RM Products with MA by Region/Country
- Approval of RM Products by Year
- Table RM Products with MA Worldwide by Year
- Number of Approved RM Products by Type
- Table RM Products with MA Worldwide by Product Type, 2018
- RM Products with MA Worldwide by Therapy Type
- Table RM Products with MA Worldwide by Therapy Type, 2018
- Indications Addressed by the Approved RM Products
- Table Number of RM Products with MA Worldwide by Indication, 2018
- Approved RM Products in Australia
- Table Cell Therapy Product with MA in Australia by TGA7
- Ortho-ACI
- RM Products Approved in Canada
- Table Cell Therapy and Gene Therapy Products with MA in Canada by Health Canada
- Gene Therapy Product Approved in China
- Table Gene Therapy Product with MA in China by CFDA8
- Approved RM Products in Europe
- Table RM Products with MA in Europe by EMA9
- Yescarta (Axicabtagene ciloleucel)
- Kymriah (Tisagenlecleucel)
- Alofisel
- Spherox
- Zalmoxix
- Strimvelis
- Imlygic (Talimogene laherparepvec)
- Holoclar
- RM Products with Withdrawn Approvals in Europe
- Table RM Products with MA Withdrawn in the E.U. by EMA
- Approved RM Products in India
- Table Cell Therapy Products with MA in India by DCGI10
- Cartigrow
- Ossgrow
- Apceden
- Stempeucel
- RM Products Approved in Japan
- Table Cell and Tissue Engineered Products with MA in Japan by PMDA11
- TEMCELL HS Inj.
- HeartSheet
- JACC
- RM Products Approved in New Zealand
- Table Cell Therapy Products with MA in New Zealand by MEDSAFE12
- Prochymal
- RM Products Approved in South Korea
- Table RM Products with MA in South Korea by MFDS13
- KeraHeal-Allo
- Neuronata-R
- Cupistem
- Cartistem
- Cellgram-AMI
- CureSkin Inj.
- Queencell
- Kaloderm
- RMS Ossron
- Immuncell LC
- CreaVax-RCC
- Kera Heal
- Chondron
- Approved RM Products in the U.S.
- HPC, Cord Blood
- Table RM Products with MA in the U.S. by FDA
- Luxturna (voretigene neparvovec-rzyl)
- Yescarta (axicabtagene ciloleucel)
- Kymriah (tisagenlecleucel)
- MACI
- Clevecord
- HPC, Cord Blood (Bloodworks)
- Imlygic (talimogenelaherparepvec)
- HPC, Cord Blood (LifeSouth Community Blood Centers)
- Allocord
- Ducord
- HPC, Cord Blood (Clinimmune Labs)
- Gintuit
- Hemacord
- Laviv (Azficel-T)
- Provenge (Sipuleucel-T)
- HPC, Cord Blood
- U.S. RM Products with RMAT Designation
- Table RM Products with RMAT14 Designation by FDA
- Pricing of RM Products
- Table Pricing of RM Products
- RM Products Expected to be Approved in Late 2019 or 2020
- Table The Five Forthcoming RM Products
- Number of RM Products Approved by Geography
- MANUFACTURING OF CELLS FOR CELL AND GENE THERAPIES
- Table Expenditure Categories in Cell Products Manufacturing
- Cost of Manufacture
- Table The Impact of Head Count on Labor Cost
- Cost of Manufacture in a Partially-Automated Facility
- Table Cost of Production in a Partially Automated Facility
- Cost of Manufacture in a Fully-Automated Facility
- Table Cost of Production in a Fully Automated Facility
- Net Present Cost (NPC) of the Three Methods
- In-House Gene Therapy Manufacturing Capabilities of Select Big and Mid Pharma
- Table In-House Gene Therapy Manufacturing Capabilities of Select Big and Mid Pharma
- External Gene Therapy Manufacturing by Big and Mid Pharma
- Table External Gene Therapy Manufacturing by Big and Mid Pharma
- Cell and Gene Therapy Manufacturing Capacities in North America
- Table Cell and Gene Therapy Manufacturing Capacities in North America
- Cell and Gene Therapy Manufacturing Capacities in Europe
- Table Cell and Gene Therapy Manufacturing Capacities in Europe
- CDMOs & CDMOs
- Table Select CDMOs in Cell and Gene Therapy Sector
- Appropriate Phase for Outsourcing
- Table The Appropriate Phase for Outsourcing a Cell or Gene Therapy Project
- Important Points Condirered while Fixing a CMO/CDMO
- Table Important Points Considered While Fixing a CDMO
- In-House vs. Outsourcing
- Table Share of In-House and CDMO Manufacture of Cell and Gene Therapies
- Number of Cell Gene Therapy CMOs/CDMOs in Europe
- Projected Growth of CMOs and CDMOs
- Projected Growth of Cell Manufacturing Capacity
- MARKET ANALYSIS
- Global Market for RM Products
- Table Global Market for RM Products by Therapy Type, 2018-2025
- Global RM Products Market by Geography
- Table Global Market for RM Products by Geography, 2018-2025
- Global Market for Cell Therapy Products
- Table Global Market for Approved Cell Therapy Products, 2018-2025
- Global Market for Gene Therapy Products
- Table Global Market for Gene Therapy Products, 2018-2025
- Competitive Landscape in Gene-Modified Cell Therapy Products
- Table Competitive Landscape in Gene-Modified Cell Therapy Products
- Global Market for Viral Vector and Plasmid DNA Manufacturing
- Table Vector and Plasmid DNA Manufacturing Market by Geography, 2018-2025
- Global Market for Tissue-Engineered Products
- Table Global Market for Tissue-Engineered Products, 2018-2025
- Global Market for RM Products
- COMPANY PROFILES
- 4D Molecular Therapeutics, LLC
- Key Capabilities
- Table 4D Molecular Therapeutics' Product Pipeline
- Key Capabilities
- Abeona Therapeutics, Inc.
- Table Abeona Therapeutics' Product Pipeline
- Adaptimmune Therapeutics plc
- Table Adaptimmune's Pipeline Programs
- Admedus Ltd.
- CardioCel
- CardioCel 3D
- VascuCel
- Advanced Bioscience Laboratories, Inc.
- Biomanufacturing Services
- Aseptic Filling Services
- Immunology and Biomarker Testing
- Contract Research Assays
- Clinical Immunology Solutions
- Preclinical Solutions
- In vivo and ex vivo Preclinical Studies
- Product Development Solutions
- Government Partnering
- Translational Product Development
- Adverum Biotechnologies, Inc.
- Akouos, Inc.
- Aldevron, LLC
- Services
- Allogene Therapeutics, Inc.
- Table Allogene Therapeutics' Pipeline of Allogeneic T-Cell Product Candidates
- AlloSource, Inc.
- Amarna Therapeutics B.V.
- Simian Virus 40 (SVac) Platform
- Ambys Medicines, Inc.
- American Gene Technologies International, Inc.
- Amgen, Inc.
- IMLYGIC (Talimogene laherparepvec)
- Amicus Therapeutics, Inc.
- Table Amicus' Gene Therapy Pipeline
- Anterogen Co., Ltd.
- Cupistem Injection
- Queencell
- APAC Biotech Pvt., Ltd.
- APCEDEN
- apceth Biopharma GmbH
- Table apceth's Pipeline Overview
- AskBio/Asclepios Biopharmaceutical, Inc.
- Table AskBio's Therapeutic Pipeline
- Asterias Biotherapeutics, Inc.
- Table Asterias' Pipeline Programs
- Atara Biotherapeutics, Inc.
- Table Atara's Pipeline of T-Cell Immunotherapy and CAR-T Product Candidates
- Athersys, Inc.
- MultiStem
- Table Athersys' Clinical Programs using MultiStem
- MultiStem
- ATVIO Biotech Ltd.
- Audentes Therapeutics, Inc.
- AT132 for X-Linked Myotubular Myopathy
- AT342 for Crigler-Najjar Syndrome
- AT982 for Pompe Disease
- AT307 for CASQ2-CPVT
- Table Audentes' Product Candidates
- AveXis, Inc.
- AVXS-101
- Avita Medical Ltd.
- RECELL System
- ReGenerCell
- ReNovaCell
- AVROBIO, INC.
- AVR-RD-01 for Fabry Disease
- AVR-RD-02 for Gaucher Disease
- AVR-RD-03 for Pompe Disease
- AVR-RD-04 for Cystinosis
- Table AVROBIO's Gene Therapy Programs
- Batavia Bioscience B.V.
- Research Services
- Development Services
- Characterization Services
- Manufacturing Services
- Consultancy Services
- Bellicum Pharmaceuticals, Inc.
- Table Bellicum Pharmaceuticals' Product Candidates
- Benitec Biopharma Limited
- Table Benitec's Product Pipeline using Gene Silencing Technologies
- Betalin Therapeutics
- Engineered Micro-Pancreas (EMP)
- BioCardia, Inc.
- Table BioCardia's Advanced Pipeline
- Biomay AG
- Biomay's Pipeline
- Table Biomay's Pipeline of Products
- Biomay's Pipeline
- BioReliance Corporation
- Biosolution Co., Ltd.
- Table Biosolution's Products and Product Candidates
- Biostage, Inc.
- Cellspan Esophageal Implants
- Cellspan Bronchial Implants
- Cellspan Tracheal Implants
- Bioverativ, Inc.
- Table Bioverativ's Product Pipeline
- Biovian Oy
- bluebird bio, Inc.
- Partnering
- Current Partners
- Table bluebird bio's Product Pipeline
- BlueRock Therapeutics
- BlueRock's Pipeline
- Bone Therapeutics SA
- ALLOB
- JTA-004
- Brainstorm Cell Therapeutics, Inc.
- NurOwn
- Table Brainstorm's Clinical Programs
- NurOwn
- Brammer Bio, LLC
- Services
- Process Development
- Gene Therapy Manufacturing
- Viral Vectors
- Caladrius Biosciences, Inc.
- Table Caladrius' Proprietary Technology Platforms and Pipeline Programs
- Carina Biotech
- CNA1003
- CARsgen Therapeutics, Ltd.
- Table CARsgen Therapeutics' Product Candidates
- Casebia Therapeutics
- Table Casebia's Pipeline at-a-glance
- Cell Cure Neurociences Ltd.
- OpRegen
- Cellerant Therapeutics, Inc.
- Table Cellerant's Program Pipeline for Blood Disorders
- Cell Medica Limited
- Table Cell Medica's Product Pipeline
- Cell Therapy Catapult, Ltd.
- Capabilities
- Cellular Biomedicine Group, Inc.
- Table CBG's Immuno-Oncology Stem Cell Therapy Pipeline
- Cellular Dynamics International, Inc.
- Celonic AG
- Celyad SA
- Table Celyad's Programs' Status at a Glance
- Cevec Pharmaceuticals GmbH
- Services
- Farmaceutici S.p.A.
- Holoclar
- Cobra Biologics Ltd.
- DNA Platform Process, Development and Scale Up
- Viral Vector Platform Process
- co-don AG
- ACT3D
- CombiGene AB
- Epilepsy Project
- Corestem, Inc.
- NEURONATA-R inj.
- Table Corestem's Key Clinical Pharmaceutical Development
- NEURONATA-R inj.
- CRISPR Therapeutics AG
- Table CRISPR Therapeutics' Clinical Programs
- CureVac
- Table CureVac's RNA-Based Product Pipeline
- Cynata Therapeutics, Ltd.
- CytomX Therapeutics, Inc.
- Table CytomX's Pipeline of Probody Therapeutics
- Cytori Therapeutics, Inc.
- Table Cytori's Cell Therapy Development Pipeline
- Delphi Genetics S.A.
- Services
- Dendreon Pharmaceuticals, Inc.
- PROVENGE
- DNAlite Therapeutics, Inc.
- Editas Medicine, Inc.
- Table Editas' Diverse Product Pipeline
- Elixirgen Therapeutics, LLC
- Table Elixirgen's Pipeline for Genetic and Age-Related Diseases
- Enzyvant, Inc.
- RVT-802
- Eukarys
- Eureka Therapeutics, Inc.
- ARTEMIS
- E-ALPHA
- Table Eureka's Development Pipeline
- Fate Therapeautics, Inc.
- Table Fate Therapeutics' Cell Therapy Product Candidates Pipeline
- Fibrocell Technologies, Inc.
- Fibrocell's Pipeline
- Table Fibrocell's Personalized Biologics Pipeline
- Fibrocell's Pipeline
- FinVector Vision Therapies Oy
- Services
- Freeline Therapeutics Ltd.
- Table Freeline's Pipeline of Gene Therapy Treatments in Development
- FUJIFILM Diosynth Biotechnologies, Inc.
- Services
- Gamida Cell Ltd.
- Table Gamida Cell's Pipeline Programs
- GC Cell
- Table Current Status of GC Cell's Clinical Activities
- Gemini Therapeutics, Inc.
- Table Gemini's Pipeline
- GEG Tech
- Lenti-ONE Vectors
- Genethon
- Table Genethon's Products in Development
- Generation Bio Co.
- Genzyme Corporation
- Epicel
- Glycostem Therapeutics BV
- Technology
- oNKord
- Hemostemix, Inc.
- Table Hemostemix's Clinical Pipeline
- Histogenics Corporation
- Homology Medicines, Inc.
- Gene Editing Platform
- Horama SAS
- Table Horama's Product Pipeline
- Humacyte, Inc.
- Immune Design Corporation
- Table Immune Design's Product Pipeline
- Immusoft Corporation
- ISP Technology
- Innovative Cellular Therapeutics Co., Ltd.
- Table ICT's Pipeline Programs
- Intellia Therapeutics, Inc.
- Table Intellia's In Vivo and Ex Vivo R&D Pipeline
- Iovance Biotherapeutics, Inc.
- Table Iovance's Clinical Pipeline
- JCR Pharmaceuticals Co., Ltd.
- TEMCELL HS Inj.
- Table JCR's RM Products in Development
- TEMCELL HS Inj.
- J-TEC
- JW CreaGene Co., Ltd.
- Products
- Kadimastem Ltd.
- AstroRx
- Incapsulin
- Kaneka Eurogentec S.A.
- KBI Biopharma, Inc.
- Kiadis Pharma N.V.
- ATIR101
- Kite Pharma, Inc.
- Yescarta
- Table Kite's CAR-T Pipeline
- Yescarta
- Kolon Lifescience, Inc.
- Invossa-K inj.
- Table Kolon's Gene Therapeutics in Development
- Invossa-K inj.
- Krystal Biotech, Inc.
- Table Krystal Biotech' Pipeline Programs for Orphan Skin Disease
- LakePharma
- Viral Vector Services
- Lion TCR Pte. Ltd.
- Table Lion TCR's Product Candidates
- Lonza Group Ltd.
- Custom Development and Manufacturing
- Lysogene S.A.
- MPS IIIA
- GM1 Gangliosidosis
- Magenta Therapeutics, Inc.
- Magenta's Programs
- Table Magenta's Product Candidates
- Magenta's Programs
- MassBiologics
- MaxCyte, Inc.
- Products
- Medigene AG
- Table Medigene's Immunotherapy Pipeline Projects
- MEDIPOST CO., Ltd.
- CARTISTEM
- PNEUMOSTEM
- NEUROSTEM
- MeiraGTx Holdings plc
- Meira's Pipeline
- Table MeiraGTX's Pipeline
- AAV-CNGB3
- AAV-RPE65
- AAV-RPGR
- AAV-AQP1
- AAV-GAD
- AAV-UPF1
- Meira's Pipeline
- Mesoblast Limited
- Table Mesoblast's Advanced Product Candidates
- Miromatrix Medical, Inc.
- MIRODERM
- MICROMESH
- MolMed S.p.A
- MolMed's Clinical Trial Programs
- MolMed's GMP Solutions
- Table MolMed's Product Candidates
- multimmune GmbH
- Platform Technology
- Mustang Bio, Inc.
- Table Mustang Bio's Product Pipeline
- MB-101
- MB-102
- MB-103
- MB-104
- MB-105
- MB-106
- MB-107
- Myonexus Therapeutics, Inc.
- Table Myonexus' Clinical Stage LGMD Gene Therapy Pipeline
- NantKwest, Inc.
- Table NantKwest's Clinical Trials using Cryopreserved haNK Cells
- NexImmune, Inc.
- Table NexImmune's Adoptive Cellular Therapy (ACT) Programs
- Nightstar Therapeutics plc
- Table Nightstar Therapeutics' Pipeline Programs
- Neuralstem, Inc.
- Table Neuralstem's Cell Therapy Programs
- Nohla Therapeutics, Inc.
- Table Nohla's Donor Cell Therapy Programs
- Novartis AG
- Kymriah
- Novasep Holding SAS
- Biopharmaceutical Manufacturing Solutions
- Noveome Biotherapeutics, Inc.
- Table Noveome's Clinical Pipeline
- NuVasive, Inc.
- Osteocel
- AttraX Scaffold
- Orchard Therapeutics plc
- Strimvelis
- OTL-101
- OTL-102
- OTL-103
- OTL-200
- OTL-201
- OTL-202
- OTL-300
- Table Orchard Therapeutics' Pipeline
- Orgenesis, Inc.
- MaSTHerCell
- Orthocell Limited
- Osiris Therapeutics, Inc.
- Grafix
- Grafix PL PRIME
- Cartiform
- BIO4
- Orthofix Medical, Inc.
- Trinity ELITE
- Trinity EVOLUTION
- VersaShield
- Oxford BioMedica plc
- Oxford BioMedica's Partnering Activities
- Table Oxford BioMedica's Proprietary Product Pipeline
- Table Oxford BioMedica's Partnered Products
- Table Oxford BioMedica's IP Enabled and Royalty Bearing Products
- Oxford BioMedica's Partnering Activities
- Oxford Genetics Ltd.
- Scalable AAV Custom Solutions
- Paragon Bioservices, Inc.
- Services
- Pharmicell Co., Ltd.
- Cellgram AMI
- Table Pharmicell's Clinical Trials for Commercialization
- Cellgram AMI
- Pluristem Therapeutics, Inc.
- Posedia Therapeutics, Inc.
- Table Posedia's Product Pipeline
- Precision BioSciences, Inc.
- ARCUS Genome Editing Platform
- Prevail Therapeutics, Inc.
- Prevail's Focus
- PROMETHERA Biosciences S.A.
- Table PROMETHERA's Product Pipeline
- PTC Therapeutics, Inc.
- Table PTC Therapeutics' Gene Therapy Programs for CNS Disorders
- Quethera Ltd.
- Technology
- Recipharm AB
- Regenerative Medical System (RMS)
- Chondron
- Ossron
- REGENXBIO, Inc.
- NAV Technology
- Therapeutic Programs
- Product Candidates
- Table REGENXBIO's Product Pipeline
- Partnerships and Licensing
- Table REGENXBIO's Partners & Licensees Pipeline
- ReNeuron Group plc
- Table ReNeuron's Program Pipeline
- Renova Therapeutics, Inc.
- Table Renova's Product Pipeline
- Richter-Helm BioLogics GmbH & Co. KG.
- Process Development
- Analytics
- Production
- Rocket Pharmaceuticals, Inc.
- RoosterBio, Inc.
- MSCs in different Formats
- Bioprocess Media
- Plug & Play Systems
- CliniControl Products
- RoslinCT
- Services
- Rubius Therapeutics, Inc.
- Table Rubius' Pipeline Programs
- Sangamo Therapeutics, Inc.
- Table Sangamo's Proprietary Programs
- Table Sangamo's Proprietary Programs
- Sarepta Therapeutics, Inc.
- Table Sarepta's Huge Product Pipeline
- SCM Lifesciences Co., Ltd.
- Table SCM Lifesciences' Product Pipeline
- Semma Therapeutics Inc.
- SCbeta Cells
- Sentien Biotechnologies, Inc.
- SBI-101
- Table Sentien's SBI-101 Clinical Programs
- SBI-101
- Sibiono GeneTech Co., Ltd.
- Gendicine
- Sirion Biotech GmbH
- Viral Vectors
- Technologies
- Solid Biosciences, Inc.
- SGT-001 (Microdystrophin Gene Transfer)
- Spark Therapeutics, Inc.
- Luxturna (voretigene neparvovec)
- Spark Therapeutics' Pipeline
- Table Spark Therapeutics' Pipeline
- SQZ Biotechnologies
- SQZ Platform
- Stempeutics Research Pvt., Ltd.
- Stempeucel
- Stempeucare
- Stempeutron
- Synpromics Ltd.
- Technology
- PromPT
- Takara Bio, Inc.
- Services and Support
- Terumo Corporation
- HeartSheet
- The Cell and Gene Therapy Catapult
- Catapult's Industrialization Team
- Catapult's Manufacturing Center at Stevenage
- Catapult's Regulatory Team
- Translate Bio, Inc.
- Table Translate Bio's Two Lead Product Candidates
- Triumvira Immunologics USA, Inc.
- Table Triumvira's Product Pipeline
- TxCell S.A.
- Technology
- CAR-Treg Transplantation (TX200)
- CAR-Treg Dermatology
- CAR-Treg Multiple Sclerosis
- Ultragenyx Pharmaceutical, Inc.
- DTX301
- DTX401
- uniQure N.V.
- Table uniQure's Product Pipeline
- Vericel Corporation
- MACI
- Epicel
- Vertex Pharmaceuticals, Inc.
- Table Vertex Pharmaceuticals' Product Candidates
- VGXI, Inc.
- ViaCyte, Inc.
- Product Candidates
- Table ViaCyte's Product Pipeline
- Product Candidates
- Vibalogics GmbH
- Vybion, Inc.
- INT41
- Table Vybion's Drug Pipeline
- INT41
- Vigene Biosciences
- Virovek, Inc.
- Custom-Made AAVs
- Vivebiotech SL
- Lentisoma Technology
- Services
- Vivet Therapeutics
- Vivet's Approach
- Voyager Therapeutics, Inc.
- Table Voyager's Pipeline Programs
- Waisman Biomanufacturing
- Services and Products
- WindMIL Therapeutics, Inc.
- Unmodified MILs
- MIL CARs
- genMILs
- Wuxi App Tec, Inc.
- Services
- Xalud Therapeutics, Inc.
- XT-101
- 4D Molecular Therapeutics, LLC
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook